In recent years, autoinjectors and pen injectors have become an increasingly important means for healthcare providers to enable safe and simple self-administration of medication for patients. With technological advances and heightened demand for self-medication to treat chronic diseases, injection systems for self-administration are now established as a user-friendly and effective solution. During the year, Nolato achieved a milestone in the Medical Solutions business area through a substantial order in this fast-growing segment, and is now expanding its production to meet global demand, especially for overweight and diabetes treatments. 
 

The success of injection systems for self-administration – improves patient independence 

Autoinjectors are becoming increasingly popular in the pharmaceutical industry to simplify self-administration of medication. They enable safe and simple administration of medication at home, especially for the treatment of chronic diseases such as diabetes, multiple sclerosis (MS), hormone therapy and weight loss, reducing the need for hospital visits and freeing up healthcare resources. The growing demand is driven by technological advances, an aging population and increased acceptance of self-medication after the pandemic. Injection systems for self-administration give a high level of conformity and minimize the risk of incorrect dosage, improving the patient’s quality of life. 
 

Major order for pen injectors for Nolato 

In 2024, Nolato secured a long-term cooperation agreement with an existing customer for the production of components for pen injectors for the treatment of diabetes and overweight, with expected annual sales of SEK 700 million. Deliveries will commence at the end of 2025, and Nolato is investing SEK 600 million in capacity expansion in Hungary, which in practice involves extending its existing premises and installing new production lines and machinery.  
 

Nolato’s combined expertise supports quality assurance 

In setting up the new production lines in Hungary, Nolato’s Technical Design Center is providing project management, quality assurance, and exchange of knowledge to ensure the best possible results in cooperation with the customer. Nolato’s sister companies are also involved to ensure the highest possible quality. Establishing an integrated production solution in Hungary strengthens Nolato’s position as a reliable partner in the pharmaceutical industry. 

Under the agreement with the customer, Nolato will manufacture pen injector components, involving injection molding and sub-assembly of the product. Manufacturing requires stable process control with high purity standards and systems that ensure that all requirements set out by industry standards are met. Nolato works closely with the customer to ensure production standards and optimize processes. 
 

Trust and expertise secure business  

Nolato’s long-term focus on security of supply, quality and precision has built up trust and secured successful business. The exacting demands of the pharmaceutical industry are met by efficient production facilities, the ability to swiftly scale up and a high level of in-house expertise, positioning Nolato as a strong partner in the industry. 

The new project marks an important step for Nolato and confirms the Group’s competitive offering in terms of capabilities for delivering large-scale solutions and creating new possibilities for future customers. Besides commercial success, it is valuable for Nolato to be part of solutions to global health challenges, helping achieve improved health and well-being through effective treatments. 

“The new project marks an important step for Nolato and confirms the Group’s competitive offering in terms of capabilities for delivering large-scale solutions and creating new possibilities for future customers.” 

 

 

Extensive investment for expanded capacity 

Nolato is investing extensively in its existing plant in Hungary to meet customer demand for pen injectors. The project can be summarized in the following figures: 

• Scope: A building of approximately 9,000 square meters is dedicated to the new production, including both conversion and extension. 
• Investment: A total of SEK 600 million is being invested in the plant, which includes production facilities, machinery and other equipment. 
• Capacity: Production will include 60 injection molding machines and three new assembly lines. 
• Financial potential: When the plant is fully utilized, annual sales are expected to amount to SEK 700 million. 
• Job creation: The new production lines will create over 200 jobs. 
• Schedule: The upgraded factory is scheduled to be operational at the end of 2025.